Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s (LSE: AZN) Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
The EGFR inhibitor showed a statistically-significant and highly clinically-meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
Results showed Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Median PFS was 39.1 months in patients treated with Tagrisso versus 5.6 months for placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze